These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 18711404)

  • 1. The use of high-sensitivity assays for C-reactive protein in clinical practice.
    Musunuru K; Kral BG; Blumenthal RS; Fuster V; Campbell CY; Gluckman TJ; Lange RA; Topol EJ; Willerson JT; Desai MY; Davidson MH; Mora S
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):621-35. PubMed ID: 18711404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease.
    Matsuo Y; Hashizume T; Shioji S; Akasaka T
    Circ J; 2008 Dec; 72(12):2046-50. PubMed ID: 18946171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Sensitivity C-Reactive Protein and Statin Initiation.
    Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
    Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
    Blake GJ; Ridker PM; Kuntz KM
    Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines.
    Mora S; Musunuru K; Blumenthal RS
    Clin Chem; 2009 Feb; 55(2):219-28. PubMed ID: 19095730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of Triclosan on Biomarkers of Cardiovascular Risk in Patients in the Cardiovascular and Periodontal Study (CAPS): A Randomized Controlled Trial.
    Cullinan MP; Palmer JE; Faddy MJ; Westerman B; Carle AD; West MJ; Seymour GJ
    J Periodontol; 2015 Jul; 86(7):847-55. PubMed ID: 25741582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?
    Gotto AM
    Trans Am Clin Climatol Assoc; 2011; 122():256-89. PubMed ID: 21686232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jupiter to Earth: CRP promotes atherothrombosis.
    Jialal I; Devaraj S
    Metab Syndr Relat Disord; 2009 Feb; 7(1):1-3. PubMed ID: 19183073
    [No Abstract]   [Full Text] [Related]  

  • 10. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
    Storey BC; Staplin N; Haynes R; Reith C; Emberson J; Herrington WG; Wheeler DC; Walker R; Fellström B; Wanner C; Landray MJ; Baigent C;
    Kidney Int; 2018 Apr; 93(4):1000-1007. PubMed ID: 29146277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is hsCRP Back on Board? Implications from the JUPITER Trial.
    Koenig W
    Clin Chem; 2009 Feb; 55(2):216-8. PubMed ID: 19074517
    [No Abstract]   [Full Text] [Related]  

  • 13. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hs-CRP in cardiovascular risk prediction.
    Am J Manag Care; 2002 Jul; Suppl Symposium Reporter():6, 8. PubMed ID: 12608152
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk.
    Cardiovasc J Afr; 2011; 22(1):51. PubMed ID: 21298210
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein and cardiovascular risk: more fuel to the fire.
    Boekholdt SM; Kastelein JJ
    Lancet; 2010 Jan; 375(9709):95-6. PubMed ID: 20031200
    [No Abstract]   [Full Text] [Related]  

  • 20. C-reactive protein levels in patients at cardiovascular risk: EURIKA study.
    Halcox JP; Roy C; Tubach F; Banegas JR; Dallongeville J; De Backer G; Guallar E; Sazova O; Medina J; Perk J; Steg PG; Rodríguez-Artalejo F; Borghi C
    BMC Cardiovasc Disord; 2014 Feb; 14():25. PubMed ID: 24564178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.